argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
Regulatory News:
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that interim data will be presented from ADAPT+ at the American Academy of Neurology (AAN) Annual Meeting in Seattle, WA, April 2-7. ADAPT+ is the global Phase 3 open-label extension study evaluating long-term efficacy, safety and tolerability of VYVGART (efgartigimod alfa-fcab) in adult patients with generalized myasthenia gravis (gMG).
Additional presentations at AAN will include a review of baseline characteristics from the Company’s pre-approval access program for VYVGART, as well as data on the treatment burden of gMG from a cross-sectional study of 152 U.S. adults with a self-reported gMG diagnosis.
“We are thrilled that our ADAPT+ study has been selected for an oral presentation at this important neurology forum, and hope these exciting data will advance healthcare providers’ understanding of long-term therapeutic outcomes with VYVGART as they continue to manage their gMG patients,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We remain as committed as ever to the gMG community, and look toward to offering deeper insight into the patient experience so we may best address their unmet needs and seek to alleviate the burden of this complex, debilitating disease.”
AAN 2022 Presentations:
Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study
Tuesday, April
5, 2022, at 4:06 PM PT
Session: S25: Autoimmune Neurology 2: Clinical Trials and Treatment; Presentation 004
Presenter: James F. Howard Jr., M.D., Professor of Neurology (Neuromuscular Disease), Medicine and Allied Health, Department of Neurology, The University of North Carolina at Chapel Hill
School of Medicine
Baseline Characteristics and Demographics of Patients Enrolled in an Expanded Access Program for Efgartigimod in Adult Patients with Generalized Myasthenia Gravis
Saturday, April 2, 2022 from 5:30 PM – 6:30 PM PT
Session: P3: Autoimmune Neurology: Peripheral Nervous System and Muscle 1; Presentation 001, Neighborhood 1
Presenter: Deborah Gelinas, M.D., Executive Director, Neuromuscular Medical Affairs, argenx
Lesen Sie auch
Treatment Burden According to Patients with Generalized Myasthenia Gravis
Sunday, April 3, 2022 from 5:30 PM – 6:30 PM PT
Session: P6: Neuromuscular Disease: Myasthenia Gravis 1; Presentation 008, Neighborhood 13
Presenter: Tuan Vu, M.D., Professor of Neurology, University of South Florida